Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) announced the appointment of Victor Bulto to its Board of Directors, effective December 1, 2025. Bulto currently leads Novartis' U.S. business, a $20+ billion operation, and brings 25 years of global healthcare leadership across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.
Labcorp highlighted his experience in transformation, technology and automation, and commercial strategy as supportive of its long-term growth priorities in precision medicine, patient access to novel therapies, and innovation through science and technology.
Labcorp (NYSE: LH) announced that Labcorp Plasma Detect, a tumor‑informed blood assay for detecting molecular residual disease (MRD) from circulating tumor DNA, was featured in two peer‑reviewed studies published Nov 19, 2025.
A Nature Medicine study in diffuse pleural mesothelioma reported that both neoadjuvant immune regimens were safe, enabled most patients to undergo surgery, and that Plasma Detect tracked early disease progression and predicted long‑term progression‑free survival. A Clinical Cancer Research study found that lymph drain fluid collected 24 hours after head and neck cancer surgery contained more tumor DNA than simultaneous plasma and that lymph‑based testing identified residual cancer missed by pathology.
Labcorp (NYSE: LH) reported third-quarter 2025 results with revenue $3.56B (up 8.6% YoY) and diluted EPS $3.12 versus $2.00 a year ago. Adjusted EPS was $4.18 (up 19.4% YoY). Operating income margin improved to 11.1% and free cash flow for the quarter was $280.5M.
The company updated 2025 guidance: enterprise revenue growth of 7.4%–8.0% (midpoint lowered ~40 bps), adjusted EPS $16.15–$16.50 (midpoint +$0.05) and free cash flow $1.17B–$1.29B (midpoint +$25M). Labcorp announced multiple asset acquisitions, a $0.72 quarterly dividend and $25M of share repurchases in the quarter.
Labcorp (NYSE: LH) will offer Roche's FDA-cleared Elecsys pTau181 blood test nationwide by early 2026 to aid initial assessment of Alzheimer's-related amyloid pathology in primary care. The test is intended for adults 55+ with cognitive complaints and measures plasma phosphorylated Tau 181. Roche reported a 97.9% negative predictive value (NPV), meaning a negative result aligns with a negative amyloid PET and lowers the likelihood that cognitive impairment is due to amyloid pathology. Testing can be performed at a clinician's office or at any of Labcorp's >2,200 patient service centers.
Praia Health, Providence, and Labcorp (LH) announced a collaboration that connected Praia Health’s patient experience platform with Labcorp’s scheduling and lab-ordering systems to streamline lab booking and patient workflows.
Key outcomes include an 8-fold increase in scheduled appointments, a 52% increase in lab bookings via digital notifications, 52% higher patient bill-pay engagement, 37% of canceled appointments rebooked within 30 days, and 23% of appointments self-modified or canceled via the app—reducing no-shows. The partners report improved patient engagement, operational efficiency, and plans to explore genomics, chronic care, at-home collection, and clinical trial recruitment.
Labcorp (NYSE: LH) announced that its Board declared a quarterly cash dividend of $0.72 per share. The dividend is payable on December 11, 2025 to shareholders of record at the close of business on November 26, 2025.
Labcorp (NYSE: LH) has announced a strategic collaboration with Roche to implement FDA-cleared VENTANA® DP 600 and DP 200 slide scanners for digital pathology. This initiative aims to transform traditional pathology by converting glass slides into high-resolution digital images, enabling remote viewing and analysis.
The collaboration comes as the U.S. faces a projected shortage of 5,700 pathologists by 2030. The digital pathology system will enhance diagnostic capabilities through improved access to expertise, streamlined workflows, and future AI integration. This builds upon Labcorp's existing relationship with Roche and extends across their Diagnostics and Biopharma Laboratory Services segments.
Labcorp (NYSE:LH), a leading global laboratory services provider, has scheduled its third quarter 2025 financial results announcement for Tuesday, October 28, 2025, before market opening.
The company will host a conference call and webcast at 9:00 AM ET to discuss the results. Investors can access the webcast through Labcorp's Investor Relations website or register for dial-in access. A replay will be available for approximately one year, until October 15, 2026.
Labcorp (NYSE: LH) has completed the acquisition of select oncology and clinical testing assets from BioReference Health, a subsidiary of OPKO Health (Nasdaq: OPK). The transaction is valued at up to $225 million, comprising $192.5 million paid at closing and a potential $32.5 million performance-based earnout.
The acquisition strengthens Labcorp's oncology testing portfolio and expands its diagnostic capabilities. BioReference Health will retain its core clinical testing operations in NY/NJ and its 4Kscore® Test franchise, which generated approximately $300 million in revenue for 2024. OPKO plans to use part of the proceeds to fund its expanded share repurchase program.
Labcorp (NYSE: LH), a leading provider of innovative laboratory services, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's executive management team will engage in a fireside chat on Tuesday, September 9, at 7:45 am ET.
Investors and interested parties can access a live audio webcast of the presentation through Labcorp's investor relations website at ir.Labcorp.com. The presentation will also be archived for future replay.